BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Donepezil; Nootropic Agents

Criteria

Inclusion Criteria:

• Subject is a nonsmoker

• Subject is in generally good health

• Subject has normal (or corrected to normal) vision and hearing

• Subject is right-handed

Exclusion Criteria:

• Subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret

• Subject has a history of stroke, seizures, or major neurological disorders

• Subject has a history of cancer

• Subject has permanent cosmetic or metallic implants that would interfere with measurements

• Subject has a history of sleep apnea

• Subject has a history of head injury/trauma